Richard Payerchin
Editor at Medical Economics
Editor at Medical Economics. Much to learn. Eager to share. And vice versa. @MedEconomics
Articles
-
1 week ago |
foodsafety.einnews.com | Richard Payerchin
Everzure, a blue food dye extracted from the algae Galdieria sulphuraria, has received approval for use by the U.S. Food and Drug Administration. This image was published on the website of the coloring creator Fermentalg. Meanwhile, FDA and the National Institutes of Health (NIH) will team up on "a new, joint innovative research initiative" devoted to analysis of ultraprocessed foods.
-
2 months ago |
patientcareonline.com | Richard Payerchin
This interview appeared originally on partner website Medical Economics. The US may be the global leader in scientific research and medicine, but the nation and its patients are not immune to problems caused by antimicrobial resistance (AMR).
-
2 months ago |
infectioncontroltoday.com | Richard Payerchin
Our sister brand, Medical Economics, first published this article. The US may be the global leader in scientific research and medicine, but the nation and its patients are not immune to problems caused by antimicrobial resistance (AMR).
-
Feb 11, 2025 |
medicaleconomics.com | Richard Payerchin
A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.
-
Feb 10, 2025 |
patientcareonline.com | Richard Payerchin
Scientific advances in cancer treatments have saved millions of lives in the United States and around the world. So have family medicine and internal medicine physicians who encourage their patients to get appropriate screenings to detect the disease as early as possible. A study titled, "Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020,” was published in JAMA Oncology in late 2024.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 29K
- DMs Open
- No
RT @IJMSCtweets: "An estimated 70% of individuals with #NMOSD can be classified as poor sleepers.... Decreased #sleep quality was significa…
If you're interested in learning more about investing in medical devices & technology, here's a great place to start: https://t.co/48nH2KfJbi @MedEconomics #Leaguemed
RT @PCPCC: In a recent @MedEconomics article, @MJH_JournalRick writes about the opportunity for value-based payment models to "enhance coll…